3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
63
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Cholangiocarcinoma
27
Pancreatic Neoplasms
26
Liver Neoplasms
18
Stomach Neoplasms
13
Esophageal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
8
Ovarian Neoplasms
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Carcinoma, Renal Cell
6
Carcinoma
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Uterine Cervical Neoplasms
4
Lung Neoplasms
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Adenocarcinoma
4
Neoplasms
3
Interventions
durvalumab
1
Observation
1
Gemcitabine
1
Cisplatin
1
Chemoradiotherapy
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Cancer Unresectable
×
durvalumab
×
Gastrointestinal
×
Clear all
NCT06591650
2026-05-14
GCND
Fudan University
Phase 2
Recruiting
33 enrolled